Immungenetics AG
- Address
- Eifflerstrasse 43, Altona-Altstadt
Sponsor Overview
Specializations
Alzheimer’s disease and early-stage dementia
Immungenetics AG focuses on clinical research in newly diagnosed early-to-mild dementia due to Alzheimer’s disease, with interest in the transition from mild cognitive impairment to early dementia.
- Early Alzheimer’s disease
- Mild cognitive impairment due to Alzheimer’s disease
- Neurodegenerative disease
The sponsor’s trial activity centers on disease-related changes in the brain linked to amyloid-beta clearance and clinical assessment in the early symptomatic stages of Alzheimer’s disease.
Neuroimaging and brain biomarker interest
The funded research includes diagnostic and therapeutic evaluation in Alzheimer’s disease, with attention to measures that reflect amyloid clearance and brain pathology in early disease.
- Aβ clearance
- Diagnostic assessment
- Biomarker-linked disease monitoring
This area reflects an interest in linking treatment effects with biological markers relevant to early neurodegeneration.
Therapeutic evaluation in cognitive decline
Clinical research activity includes the assessment of thiethylperazine as a potential therapeutic agent in patients with early cognitive symptoms associated with Alzheimer’s disease.
- Symptomatic cognitive impairment
- Early dementia treatment
- Drug repurposing in neurology
The sponsor’s therapeutic interest is concentrated on interventions intended for the early clinical course of Alzheimer-related cognitive deterioration.
Clinical development in neurology
Immungenetics AG’s research portfolio is centered on a single neurology-focused program conducted across multiple collaborating sites in Germany.
- Multisite clinical research
- Alzheimer-focused development
- Early intervention strategies
The sponsor’s activity is directed toward clinical questions in the management of early-stage neurocognitive disorders.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 2 Theranostic Trial Evaluating the Effects of Thiethylperazine in Patients Diagnosed with an Early Stage of Alzheimer's disease |  Germany | Not Yet Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 8 sites across their trial portfolio.
Therapeutic Focus
- 1.Mental Disorders1 trial150 other sponsors
Partnered Research Centres
8 centres- Address
- Luisenring J 5, 68159 Mannheim
- Address
- Albert-Einstein-Allee 23, Eselsberg, 89081 Ulm
- Address
- Ziemssenstrasse 1, Ludwigsvorstadt-Isarvorstadt, 80336 Munich
- Address
- Carl-Neuberg-Strasse 1, Gross Buchholz, 30625 Hanover
- Address
- Ernst-Heydemann-Strasse 6, Hansaviertel, 18057 Rostock
- Address
- Hufelandstrasse 55, Holsterhausen, 45147 Essen
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Immungenetics AG.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.